TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27903924

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (20 mg/m2, increased to 25 mg/m2 for subsequent cycles if tolerated)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Methotrexate (40 mg/m2/week)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 101

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 101
Study: 24468015

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 14
Study: 22607512

Group type: EXPERIMENTAL
Intervention: Thyroid fine-needle biopsy (FNB)
Number of subjects: 110
Study: 20403951

Group type: EXPERIMENTAL
Intervention: Deltapaq coil (Micrus Endovascular)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Helipaq coil (Micrus)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ultipaq coil (Micrus)
Number of subjects: 15
Study: 18575944

Group type: EXPERIMENTAL
Intervention: Autograft hamstring tendon constructs
Number of subjects: 84

Group type: COMPARATOR
Intervention: Allograft constructs
Number of subjects: 84
Study: 16205597

Group type: EXPERIMENTAL
Intervention: Doxorubicin and cyclophosphamide (AC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxanes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose dense chemotherapy incorporating AC and paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen (T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ovarian suppression combined with an AI
Number of subjects: 0
Study: 12122630

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and tobramycin with dexamethasone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ciprofloxacin and tobramycin without dexamethasone
Number of subjects: 80
Study: 10368248

Group type: EXPERIMENTAL
Intervention: 7-day frequency-volume (FV) chart
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (11 men, mean age 63.3 years, range 58‐69)
Number of subjects: 23
Study: 8901799

Group type: EXPERIMENTAL
Intervention: Sour milk (Calpis), 95 mL daily for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (artificially acidified milk), 95 mL daily for 8 weeks
Number of subjects: 30
Study: 1812906

Group type: EXPERIMENTAL
Intervention: Supervised brushing program (at least 70% compliance)
Number of subjects: 2415

Group type: EXPERIMENTAL
Intervention: Supervised brushing program
Number of subjects: 2415

Group type: EXPERIMENTAL
Intervention: Higher fluoride dentifrice (1,500 ppm F MFP)
Number of subjects: 2415
Study: 6848468

Group type: EXPERIMENTAL
Intervention: Treatment group (n = 50)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Comparison group (n = 50)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Midrange blood pressure comparison group (n = 50)
Number of subjects: 150
Study: 29480175

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) in blood pressure (BP)
Number of subjects: 2305
Study: 26541103

Group type: EXPERIMENTAL
Intervention: Central air injection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Peripheral air injection
Number of subjects: 48
Study: 24630347

Group type: EXPERIMENTAL
Intervention: Early enteral fat supplement and fish oil
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 36
Study: 22705237

Group type: EXPERIMENTAL
Intervention: Telecounseling (7 sessions over 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 40
Study: 19821068

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation (ALP) applied to the left forearms of BD patients
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Skin pathergy test (SPT) performed on both forearms of BD patients
Number of subjects: 35
Study: 17698733

Group type: EXPERIMENTAL
Intervention: cTnT assay (detection limit < or = 0.01 ng/mL)
Number of subjects: 4053

Group type: EXPERIMENTAL
Intervention: hsTnT assay (detection limit < or = 0.001 ng/mL)
Number of subjects: 4053

Group type: EXPERIMENTAL
Intervention: hsTnT assay added to models adjusted for clinical risk factors
Number of subjects: 4053
Study: 15694874

Group type: EXPERIMENTAL
Intervention: Forgiveness-related constructs assessment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: State anger mediation analysis
Number of subjects: 61
Study: 12192353

Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup (10 mg/kg 3 times a day for 5 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup
Number of subjects: 36
Study: 10665199

Group type: EXPERIMENTAL
Intervention: Intra‐oral fluoride releasing device (IFRD) releasing 0.04 mg/day of fluoride for 12 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no fluoride device)
Number of subjects: 76
Study: 7637525

Group type: EXPERIMENTAL
Intervention: Podiatric orthoses supplied to the experimental group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no podiatric orthoses)
Number of subjects: 0
Study: 2566250

Group type: EXPERIMENTAL
Intervention: Midazolam (0.25 mg kg‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thiopentone (5 mg kg‐1)
Number of subjects: 20
Study: 998556

Group type: EXPERIMENTAL
Intervention: Raw wheat bran 12 g/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Raw wheat bran 20 g/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cooked bran 13.2 g/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cooked bran 22 g/day
Number of subjects: 10
Study: 31836474

Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EAC)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 154
Study: 31601496

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg intravenous, administered 1-42 days after chemoradiotherapy, then every 2 weeks up to 12 months)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Placebo (matching placebo administered 1-42 days after chemoradiotherapy, then every 2 weeks up to 12 months)
Number of subjects: 713
Study: 27032655

Group type: EXPERIMENTAL
Intervention: About Face program plus Individual Placement and Support (AF+IPS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: About Face program (AF)
Number of subjects: 84
Study: 25140956

Group type: EXPERIMENTAL
Intervention: Regular blood transfusions
Number of subjects: 196

Group type: COMPARATOR
Intervention: Standard care (observation)
Number of subjects: 196
Study: 23529392

Group type: EXPERIMENTAL
Intervention: Hippophae rhamnoides
Number of subjects: 120

Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hippophae rhamnoides plus domperidone
Number of subjects: 120
Study: 20947933

Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy
Number of subjects: 501

Group type: COMPARATOR
Intervention: Manual aspiration catheter
Number of subjects: 501

Group type: COMPARATOR
Intervention: Mechanical thrombectomy devices
Number of subjects: 501
Study: 17627100

Group type: EXPERIMENTAL
Intervention: Assisted pressure-controlled ventilation (APCV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pressure-support ventilation (PSV)
Number of subjects: 34
Study: 17203750

Group type: EXPERIMENTAL
Intervention: HAI plus systemic chemotherapy (HAI+SYC)
Number of subjects: 76

Group type: COMPARATOR
Intervention: HAI
Number of subjects: 76
Study: 14622075

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral analysis system of psychotherapy (CBASP) with medication
Number of subjects: 367

Group type: COMPARATOR
Intervention: Cognitive‐behavioral analysis system of psychotherapy (CBASP) alone
Number of subjects: 367
Study: 10764306

Group type: EXPERIMENTAL
Intervention: Automatic PSV
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard PSV
Number of subjects: 10
Study: 8958493

Group type: EXPERIMENTAL
Intervention: Ketamine 3 mg kg‐1
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ketamine 6 mg kg‐1
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (cola 0.2 mL kg‐1)
Number of subjects: 43
Study: 7837987

Group type: EXPERIMENTAL
Intervention: Hoffman's nipple stretching exercises
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Breast shells
Number of subjects: 463

Group type: COMPARATOR
Intervention: No Hoffman's exercises
Number of subjects: 463

Group type: COMPARATOR
Intervention: No breast shells
Number of subjects: 463
Study: 3293643

Group type: COMPARATOR
Intervention: 0.125% bupivacaine in 0.9% saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: diamorphine in 0.9% saline (0.5 mg in 15 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: diamorphine mixed with 0.125% bupivacaine (0.5 mg in 15 ml)
Number of subjects: 0
Study: 30903368

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (pelvic floor muscle exercises and self-management skills)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study: 28566304

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 51

Group type: COMPARATOR
Intervention: CKD patients without HD
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All CKD patients
Number of subjects: 51
Study: 29348380

Group type: EXPERIMENTAL
Intervention: Nigella sativa seed extract 300 mg twice daily for 28 days
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 23706428

Group type: EXPERIMENTAL
Intervention: Supervised training with a CT surgeon or fellow on a low-fidelity task simulator
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Unsupervised training on a low-fidelity task simulator
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 45
Study: 21849027

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) combined with treatment as usual
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study: 19022547

Group type: EXPERIMENTAL
Intervention: Standard multivitamin containing high doses of folic acid and vitamins B(6) and B(12)
Number of subjects: 4110

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 4110
Study: 17252186

Group type: EXPERIMENTAL
Intervention: Vincristine during involved field radiotherapy, followed by six cycles of prednisone, lomustine, and vincristine
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Two cycles of 'eight-drugs-in-one-day' (8-in-1) chemotherapy followed by involved-field radiotherapy and six cycles of 8-in-1 chemotherapy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Institutional diagnosis of AMG
Number of subjects: 250

Group type: COMPARATOR
Intervention: Institutional diagnosis of AO
Number of subjects: 250
Study: 15016257

Group type: EXPERIMENTAL
Intervention: DOXY
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ATRI
Number of subjects: 10
Study: 12808771

Group type: COMPARATOR
Intervention: No fluid
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 18
Study: 9000222

Group type: EXPERIMENTAL
Intervention: Patients with hypothalamic insufficiency
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 10
Study: 1732770

Group type: EXPERIMENTAL
Intervention: Nonionic, low-osmolality radiocontrast agents
Number of subjects: 737

Group type: COMPARATOR
Intervention: Ionic, high-osmolality radiocontrast agents
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 737
Study: 6691786

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride (2 micrograms/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31436835

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily (QD)
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Enoxaparin/warfarin
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Age ≥75 years
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Lower weight
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Lower creatinine clearance
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Diuretic treatment
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Anticoagulation use prior to enrolment
Number of subjects: 2199

Group type: EXPERIMENTAL
Intervention: Age and heart failure
Number of subjects: 2199
Study: 29893767

Group type: EXPERIMENTAL
Intervention: Noninvasive swallowing metrics (maximal tongue strength, hand grip strength, pharyngeal volume, age, body mass index, 3-oz water swallow challenge, 10-item Eating Assessment Tool, Frailty Index)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Pharyngeal volume
Number of subjects: 44
Study: 26915483

Group type: EXPERIMENTAL
Intervention: CUR 320 mg/day
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 24200201

Group type: EXPERIMENTAL
Intervention: Energy enriched meals (standard texture; 315 kcal)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Energy enriched meals (texture modified; 303 kcal)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Energy enriched meals (standard texture)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Energy enriched meals (texture modified)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Texture modified meals
Number of subjects: 33
Study: 21802222

Group type: EXPERIMENTAL
Intervention: Job Seekers' Workshop (JSW)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 628
Study: 19569006

Group type: EXPERIMENTAL
Intervention: Small-sided game (SSG) training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Generic training group (GTG)
Number of subjects: 25
Study: 17289537

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered once monthly
Number of subjects: 0
Study: 15362382

Group type: EXPERIMENTAL
Intervention: Ambient odor (lavender, neroli) with relaxing suggestion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ambient odor (lavender, neroli) with stimulating suggestion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo with relaxing suggestion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo with stimulating suggestion
Number of subjects: 90
Study: 11434170

Group type: EXPERIMENTAL
Intervention: HLA class II antigens typing in children with MCNS and glomerulosclerosis (progressive state from minimal lesions)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: HLA class II antigens typing in children with idiopathic FSGS
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (51 healthy unrelated individuals)
Number of subjects: 38
Study: 14518297

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (POF)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 51
Study: 9663889

Group type: EXPERIMENTAL
Intervention: Mupirocin ointment applied at the catheter exit site (daily or three times per week)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Mupirocin ointment applied at the catheter exit site
Number of subjects: 181
Study: 2495214

Group type: EXPERIMENTAL
Intervention: Lactose-free pelletized sodium cromoglycate (20 mg)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Sodium cromoglycate plus lactose (20 mg)
Number of subjects: 529
Study: 841307

Group type: COMPARATOR
Intervention: 10 mg cocaine hydrochloride intranasally
Number of subjects: 19

Group type: COMPARATOR
Intervention: 25 mg cocaine hydrochloride intranasally
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 100 mg cocaine hydrochloride intranasally
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 10 mg cocaine hydrochloride intravenously
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 25 mg cocaine hydrochloride intravenously
Number of subjects: 19
Study: 31141505

Group type: EXPERIMENTAL
Intervention: Cinacalcet treatment
Number of subjects: 3276
Study: 29937865

Group type: EXPERIMENTAL
Intervention: ART/TB treatment arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Withdrawing ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: TB alone treatment arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 0
Study: 26426113

Group type: EXPERIMENTAL
Intervention: Spectacle ownership among migrant children needing glasses (147 of 640 children, 23.0%)
Number of subjects: 4409

Group type: EXPERIMENTAL
Intervention: Having uncorrected visual acuity less than 6/18 in both eyes
Number of subjects: 4409
Study: 23690688

Group type: EXPERIMENTAL
Intervention: Effective CPAP (4-15 mm H2O)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo CPAP (pressure 4 mm H2O)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Antihypertensive treatment alone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of antihypertensive treatment with effective CPAP
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with effective CPAP
Number of subjects: 44

Group type: COMPARATOR
Intervention: Antihypertensive treatment
Number of subjects: 44
Study: 21950232

Group type: EXPERIMENTAL
Intervention: Propofol intravenously (Group A)
Number of subjects: 96

Group type: COMPARATOR
Intervention: 10 ml of 2% Lidocaine Hydrochloride into the fracture hematoma (Group B)
Number of subjects: 96
Study: 19801055

Group type: EXPERIMENTAL
Intervention: Time Pressure Management (TPM) strategy, 10 hours of treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 37
Study: 16412737

Group type: EXPERIMENTAL
Intervention: Bilateral transfer of injected oocytes into two tubes
Number of subjects: 160

Group type: COMPARATOR
Intervention: Unilateral transfer of injected oocytes into one tube
Number of subjects: 160
Study: 15623179

Group type: EXPERIMENTAL
Intervention: Counselling by minimally trained community counsellors for 4 weeks
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Counselling by minimally trained community counsellors for 8 weeks
Number of subjects: 366

Group type: COMPARATOR
Intervention: Control group (initially not counselled, later counselled for ethical reasons)
Number of subjects: 366
Study: 11740134

Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 138
Study: 9002942

Group type: EXPERIMENTAL
Intervention: Epoetin beta (5 x 500 U/kg body weight intravenously over 14 days)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (intravenously over 14 days)
Number of subjects: 76
Study: 8097614

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 1110
Study: 3316296

Group type: EXPERIMENTAL
Intervention: Chlorhexidine acetate chewing gum (5 mg per piece)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorhexidine acetate chewing gum with hydrogen peroxide releasing agent
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control gum (gum base with flavoring agents, no CHX or H2O2)
Number of subjects: 12
Study: 30301557

Group type: COMPARATOR
Intervention: Group A (without preoperative fractured ankle CT scan)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Group B (with preoperative fractured CT scan)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Group C (with preoperative bilateral ankle CT analysis)
Number of subjects: 51
Study: 28410612

Group type: EXPERIMENTAL
Intervention: NoPALM formula
Number of subjects: 33

Group type: COMPARATOR
Intervention: PALM formula
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 33
Study: 26044391

Group type: EXPERIMENTAL
Intervention: Lysine-derived urethane adhesive (Treatment group)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (surgical drains)
Number of subjects: 130
Study: 22884667

Group type: EXPERIMENTAL
Intervention: Yoga sessions (one-hour, three times a week from the 12th to the 28th week of gestation)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional antenatal exercises (walking)
Number of subjects: 68
Study: 20410465

Group type: EXPERIMENTAL
Intervention: Free and Cued Selective Reminding Test (FCSRT)
Number of subjects: 1663
Study: 19076089

Group type: EXPERIMENTAL
Intervention: Irbesartan (I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan (V)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine (A)
Number of subjects: 0
Study: 15984585

Group type: EXPERIMENTAL
Intervention: Conventional mono mac therapy (20 mg twice a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mono mac chronotherapy (10 to 20 mg 30 minutes before PMI episodes)
Number of subjects: 60
Study: 12610046

Group type: EXPERIMENTAL
Intervention: GLP-1 at a dose of 1.5 pmol.kg(‐1)x min(‐1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no GLP-1)
Number of subjects: 11
Study: 10496529

Group type: EXPERIMENTAL
Intervention: MSI-H gastric adenomas
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: MSI-H gastric carcinomas
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: MSI-L gastric adenomas
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: MSI-L gastric carcinomas
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Frameshift mutations in MSI-H tumors
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: MSI-L tumors
Number of subjects: 223

Group type: COMPARATOR
Intervention: Comparison of mutations between MSI-H adenomas and MSI-H carcinomas
Number of subjects: 223
Study: 8621746

Group type: EXPERIMENTAL
Intervention: Fenfluramine (60 mg oral dose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1769410

Group type: EXPERIMENTAL
Intervention: Papaverine hydrochloride (150-300 mg t.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Papaverine hydrochloride
Number of subjects: 20
Study: 7107102

Group type: EXPERIMENTAL
Intervention: Individual Anaerobic Threshold (IAT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fixed Anaerobic Threshold of 4 mmol.l(-1) lactate (ATc)
Number of subjects: 19
Study: 31682026

Group type: EXPERIMENTAL
Intervention: 1-L PEG, 4 h before VCE
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: 1-L PEG, 12 h before VCE
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: 2-L PEG, 12 h before VCE
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: 2-L PEG, 4 h before VCE
Number of subjects: 410

Group type: COMPARATOR
Intervention: no PEG
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: 1-L PEG
Number of subjects: 410